ATLANTA, December 23, 2022 — Lipogems, a clinical-stage global medical technology company that uses autologous adipose tissue for therapeutic use in orthopedics and other specialties, today announced that it has raised €12.5 million (approximately USD 13.2 million) in growth capital for 2022 to support the recently FDA-approved IDE Studies for a separate and specific indication in Knee Osteoarthritis (OA).
The present economic scale of osteoarthritis medicines is around $7 billion, with a projected increase of USD 16 billion by 2030. Lipogems’ minimally invasive technique takes around 40 minutes and is performed once in a sterile setting (outpatient or operating room) and has been demonstrated in independent, investigator-initiated trials to enhance pain, function, and quality of life in patients with this severe condition.
“Lipogems is the proven leader in adipose tissue technology in this highly regulated industry, with 60,000 operations conducted to date in 250+ US orthopedic hospitals and military facilities. Over 35 of the 125+ peer-reviewed articles supporting Lipogems are in Knee OA. This FDA trial will demonstrate the favorable effects routinely seen in this standard and debilitating condition. This research and new financing reinforce our cautious regulatory and commercialization plan and our shareholders’ faith in Lipogems. Our aim is to give easy and effective treatment options for common disabling ailments “Carl Llewellyn, CEO and President of Lipogems USA, said.
ABC Medtech and LIFTT investors are giving Lipogems with the financial resources needed to:
- Build infrastructure to support expansion by paving the road for a knee OA indication and reimbursement in the United States.
- Educate and promote awareness of knee OA among consumers and patients.
- Expand into new areas where there are prevalent illnesses with few treatment alternatives and where MicroFat can bring life-changing relief.
The investors conducted extensive due diligence as part of the transaction to validate the regulatory strategy and overall investment in the company, with assistance from Mazars and Fantozzi & Ass. (financial, accounting, and tax matters), Bonelli, Erede, and Partners (legal), Nomisma (business), and Intexo SB (regulatory).
Lipogems is a privately held medical device firm that employs adipose tissue treatments to assist patients in maintaining or restore their lives, enhancing quality of life, and shortening recovery times. Lipogems’ products are utilized in various fields, including orthopedics, general surgery, cosmetic and reconstructive surgery, wound care, and more. Lipogems is offered in 29 countries to resume people’s lives through our worldwide reach and scientific brilliance.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
 in growth capital for 2022 to support the recently FDA-approved IDE Studies for a separate and specific indication in Knee Osteoarthritis (OA).){kind=link}